Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F. Descamps D, et al. Among authors: peytavin g. JAMA. 2000 Jan 12;283(2):205-11. doi: 10.1001/jama.283.2.205. JAMA. 2000. PMID: 10634336 Clinical Trial.
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL. Duval X, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2002 Feb;46(2):570-4. doi: 10.1128/AAC.46.2.570-574.2002. Antimicrob Agents Chemother. 2002. PMID: 11796381 Free PMC article.
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. Among authors: peytavin g. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group. Descamps D, et al. Among authors: peytavin g. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. doi: 10.1097/00126334-200212150-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12473833 Clinical Trial.
Clinically relevant interpretation of genotype for resistance to abacavir.
Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D; Narval (ANRS 088) Study group. Brun-Vézinet F, et al. Among authors: peytavin g. AIDS. 2003 Aug 15;17(12):1795-802. doi: 10.1097/00002030-200308150-00008. AIDS. 2003. PMID: 12891065
Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group. Vray M, et al. Among authors: peytavin g. Antivir Ther. 2003 Oct;8(5):427-34. doi: 10.1177/135965350300800510. Antivir Ther. 2003. PMID: 14640390 Clinical Trial.
484 results